Most IBS patients who responded to fecal transplantation maintained this response after 1 year. Improvements in symptoms, quality of life, fecal bacterial profile, and short-chain fatty acids increased significantly.
Results from the LAUREL trial showed that despite nominally significant benefits with etrolizumab, endoscopic remission and histologic remission was not met in a cohort of TNF-naïve ulcerative colitis patients.
Filgotinib was effective and well-tolerated as maintenance treatment for patients with moderately to severely active ulcerative colitis who had achieved a clinical response to induction treatment with this drug.
Weekly dupilumab demonstrated significant and clinically meaningful improvements in histologic, symptomatic, endoscopic, and molecular aspects of eosinophilic esophagitis (EoE).
Hackers use the ransomware technique to block a computer network and demand a ransom to restore access to it. A first (indirect) death caused by such an attack occurred in a German hospital.
An analysis of an Australian tertiary health network showed a significant improvement in overall sessile serrated adenoma detection rate (SSADR) over a 4-year period.
Post-colonoscopy colorectal cancers accounted for a substantial proportion of all IBD-related colorectal cancers. However, IBD patients had a low absolute risk of post-colonoscopy colorectal cancers.
Mirikizumab demonstrated sustained efficacy at week 52 in patients with moderate-to-severe Crohn’s disease. In the maintenance period of the phase 2 SERENITY trial, few patients discontinued due to adverse events.
A Japanese study showed that the presence or absence of cholecystectomy does not affect biliary tract problems or mortality in patients ≥80 years old. Follow-up may be appropriate, without surgery.
The uroguanylin-analog plecanatide is an effective symptomatic treatment for patients with IBS-C. An early clinical response appeared to be predictive of overall response after 12 weeks.
TNF antagonists do not appear to be associated with severe COVID-19, a large, international registry to monitor outcomes of IBD patients with confirmed COVID-19 found.
High-quality therapeutic ERCP, EUS, luminal stenting, and dilatation, can be delivered safely to appropriately prioritized patients during the COVID-19 pandemic.
The SARS-CoV-2 vaccine race meets the US presidential race, turning vaccine development into a political propaganda topic and pushing pharma companies to publish ongoing trial protocols for transparency.
STARDUST is the first randomized treat-to-target trial using endoscopy at week 16 to guide dose escalation in Crohn’s disease patients. T2T could be an additional tool for ustekinumab dosing decisions.
Sports are key for this patient group. Hypoglycemia should be avoided by supplementing carbohydrate intake, preprandial and basal insulin doses reduction, and combining aerobic exercise with other activities.
Oncological treatment with PD1 or PD-L1 inhibitors can trigger type 1 diabetes. This undesirable effect usually occurs early, often accompanied by acute ketoacidosis. Current data on the issue were presented.
People who suffer from diabetes mellitus and have elevated uric acid levels, often also have diabetic nephropathy. The question was clearly answered: uric acid is a biomarker and not a risk factor.
Hypoglycemia in diabetes types 1 and 2 patients has not decreased in recent years despite numerous improvements. The role of C-peptide in hypoglycemia and modern techniques to prevent it were discussed.
This story highlights the shortcomings of the scientific publication system. At a time when studies are unveiled on social networks, collaborative reviewing must be strengthened and expanded.
Dapagliflozin reduced kidney failure risk in patients with CKD, the risk of cardiovascular death or hospitalization due to heart failure, and the SGLT2 inhibitor prolonged survival.